IMVEXXY offers an elegant design that fits into her life

IMVEXXY is a vaginal estrogen treatment option for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. Vulvar and vaginal atrophy may also be known as vulvovaginal atrophy, atrophic vaginitis, or vaginal atrophy.4

IMVEXXY is a bio-identical,* softgel vaginal insert that offers an applicator-free experience with mess-free administration, no dose preparation, and any time of day dosing, which may help support patient compliance. IMVEXXY is the only ultra-low-dose vaginal estradiol available in both 4-mcg and 10-mcg doses.1,2,5,6

*The relevance of risks associated with the use of synthetic hormones compared to bio-identical hormones is not known but cannot be excluded.

4. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068.

The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Contraindications

IMVEXXY® is contraindicated in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to IMVEXXY; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

Warning and Precautions

IMVEXXY is intended only for vaginal administration. Systemic absorption may occur with the use of IMVEXXY.

The use of estrogen-alone and estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.

The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.

Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.

Women on thyroid replacement therapy should have their thyroid function monitored.

Adverse Reactions

The most common adverse reaction with IMVEXXY (incidence ≥3 percent) and greater than placebo was headache.